Postdoctoral Scientist: Clinical and Experimental Pharmacology Group
£31,604 – £41,929 per annum (dependent upon qualifications and experience)
Fixed term for 3 years
About the role:
A 3 year postdoctoral position is available within the Clinical and Experimental Pharmacology Group led by Prof Caroline Dive CBE to conduct innovative translational research on Small Cell Lung Cancer (SCLC). This is an aggressive and highly metastatic disease with dismal prognosis in need of better and personalised therapies.
You will build upon our established research programme on SCLC Vasculogenic Mimicry (VM)1. VM occurs when tumour cells undergo trans-endothelial differentiation and in so doing, acquire the ability to form perfusable vascular networks independent of host angiogenesis. VM is an adaptive process that enables tumour growth under limiting oxygen/nutrient conditions. It is associated with poorer patient outcomes in a range of human cancers including SCLC.
The ultimate aim of this research programme is to define the impact on VM on SCLC behaviour (tumour growth, therapy responses and dissemination) and identify tractable targets via a mechanistic understanding of VM regulation. The project is underpinned by our 45 comprehensively characterised SCLC Circulating Tumour Cell (CTC) derived explant models (CDX) that can be grown as short term cultures ex vivo allowing genetic manipulation and function testing studies4. VM will also be studied in genetically engineered in vivo models of SCLC expanding our joint studies with Prof Julien Sage (Stanford University, CA, USA). SCLC CDX cells enable VM vessel formation via remodelling of the surrounding extracellular matrix and the post holder will also benefit from on-going collaboration with integrin signalling and adhesome expert, Prof. Martin Humphries (University of Manchester)5.
1Williamson et al., Nature Comms (2016);
2 Hodgkinson et al., Nature Medicine (2014);
3Simpson et al, in review (2019);
4Lallo et al., Clin Cancer Research (2018); 5Byron et al., Nat Comms (2015).
You will be highly motivated and develop your independent ideas for project delivery. You will have a PhD in cancer biology, oncology, cell biology, molecular pharmacology or a related discipline and relevant experience in an internationally recognised cancer research laboratory. Prior experience in vascular biology or lung cancer research would be an advantage.
Why choose Cancer Research UK Manchester Institute?
The Cancer Research UK Manchester Institute (www.cruk.manchester.ac.uk), an Institute of The University of Manchester (www.manchester.ac.uk), is a world-leading centre for excellence in cancer research. The Institute is core funded by Cancer Research UK (www.cancerresearchuk.org), the largest independent cancer research organisation in the world. We are currently situated at the internationally-renowned life sciences campus at Alderley Park in Cheshire England, 15 miles from Manchester, a vibrant and dynamic city surrounded by beautiful countryside.
Our aim is to understand the fundamental basis of cancer and apply that knowledge to developing new treatment strategies for cancer patients. Our advanced research programmes span a spectrum of cancer research, from the molecular and cellular basis of cancer through to drug discovery, translational research and clinical trials.
Informal enquiries should be directed to Professor Caroline Dive via email: Caroline.Dive@cruk.manchester.ac.uk or to her Preclinical Pharmacology Team lead Dr Kathryn Simpson via email: Kathryn.Simpson@cruk.manchester.ac.uk
How to apply?
To apply for this position please visit our website: https://www.cruk.manchester.ac.uk/recruitment/candidate/searchvacancies
Closing date: at 11:59pm 26 September 2019.
Cancer Research UK Manchester Institute is a Research Institute within The University of Manchester and is core funded by Cancer Research UK